Gender effects on intramuscular interferon beta-1a in relapsing–remitting multiple sclerosis: analysis of 1406 patients

Abstract

Background: We aimed to evaluate effects of gender on efficacy and safety of intramuscular (IM) interferon beta (IFNβ)-1a in patients with relapsing–remitting MS (RRMS) or clinically isolated syndromes (CIS) characteristic of early MS.

Methods: Pooled data from 1406 (1027 women; 379 men) patients enrolled in five clinical studies of IM IFNβ-1a were analyzed. One analysis examined data for all patients treated with IM IFNβ-1a from all studies. Separate analyses were conducted of pooled IM IFNβ-1a-treated groups from all studies and pooled IFNβ-1a-treated and placebo-treated patients from the placebo-controlled studies. Outcome measures included time to first relapse, annualized relapse rate, time to disability progression, number of gadolinium-enhanced lesions, adverse events, laboratory evaluations, and neutralizing antibodies.

Results: All efficacy assessments indicated similar treatment effects of IM IFNβ-1a in men and women with no significant treatment-by-gender interactions. Women reported more headaches, urinary tract infections, and depression in the analysis; however, these were also common in women who received placebo. Men reported more frequent flu-like symptoms in the placebo-controlled studies only. There were no other differences in the safety profile of IM IFNβ-1a between men and women.

Conclusions: We conclude that no significant gender-related differences were found in the efficacy and safety of IM IFNβ-1a in patients with RRMS or CIS.

Keywords

Adverse events annualized relapse rate clinically isolated syndrome disability progression gadolinium-enhanced lesions IM IFNβ-1a multiple sclerosis neutralizing antibodies relapsing-remitting multiple sclerosis

Get full access to this article

View all access options for this article.

References

Food and Drug Administration. Summary basis for approval: interferon beta-1a. http://www.fda.gov/cder/biologics/sba/ifnbbio051796s.pdf. (published 17 February 2005; accessed 7 September 2006).

Tomassini

Paolillo

Russo

Giugni

Prosperini

Gasperini

. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006; 253: 287–293.

Monzani

Caraccio

Meucci

Lombardo

Moscato

Casolaro

. Effect of 1-year treatment with interferon-β1b on thyroid function and autoimmunity in patients with multiple sclerosis. Eur J Endocrinol 1999; 141: 325–331.

Jacobs

Cookfair

Rudick

Herndon

Richert

Salazar

. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285–294.

Jacobs

Beck

Simon

Kinkel

Brownscheidle

Murray

. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898–904.

Clanet

Radue

Kappos

Hartung

Hohlfeld

Sandberg-Wollheim

. A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS. Neurology 2002; 59: 1507–1517.

Herndon

Rudick

Munschauer

III Mass

Salazar

Coats

. Eight-year immunogenicity and safety of interferon beta-1a-Avonex® treatment in patients with multiple sclerosis. Mult Scler 2005; 11: 409–419.

Phillips

Rice

Frohman

Vande Gaer

Scott

Haas

. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. Clin Ther 2004; 26: 511–521.

Johnson

Brooks

Cohen

Ford

Goldstein

Lisak

. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998; 50: 701–708.

10.

IFNβ Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655–661.

11.

Johnson

Brooks

Cohen

Ford

Goldstein

Lisak

. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268–1276.

12.

PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498–1504.

13.

European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491–1497.

14.

Comi

Filippi

Wolinsky

the European/Canadian Glatiramer Acetate Study

Group

. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49: 290–297.

15.

Comi

Filippi

Barkhof

Durelli

Edan

Fernández

. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576–1582.

16.

Durelli

Verdun

Barbero

Bergui

Versino

Ghezzi

. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453–1460.

17.

Panitch

Goodin

Francis

Chang

Coyle

O’Connor

. Randomized, comparative study of interferon β-1a treatment regimens in MS. The EVIDENCE trial. Neurology 2002; 59: 1496–1506.

18.

North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS. Results from a 3-year controlled study. Neurology 2004; 63: 1788–1795.

19.

Freedman

Francis

Sanders

Rice

O’Connor

Comi

. Randomized study of once-weekly interferon β-1a therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler 2005; 11: 41–45.

20.

Filippi

Wolinsky

Comi

and the CORAL Study Group. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol 2006; 5: 213–220.

21.

Kappos

Polman

Freedman

Edan

Hartung

Miller

. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242–1249.

22.

Kappos

Freedman

Polman

Edan

Hartung

Miller

. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370: 389–397.

23.

Patten

Metz

Reimer

. Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Mult Scler 2000; 6: 115–120.

24.

Khan

McPhail

Brand

Turner-Stokes

Kilpatrick

. Multiple sclerosis: disability profile and quality of life in an Australian community cohort. Int J Rehabil Res 2006; 29: 87–96.

25.

Zephir

De Seze

Stojkovic

Delisse

Ferriby

Cabaret

. Multiple sclerosis and depression: influence of interferon β therapy. Mult Scler 2003; 9: 284–288.

26.

Patten

Fridhandler

Beck

Metz

. Depressive symptoms in a treated multiple sclerosis cohort. Mult Scler 2003; 9: 616–620.

27.

Galeazzi

Ferrari

Giaroli

Mackinnon

Merelli

Motti

. Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy. Neurol Sci 2005; 26: 255–262.

28.

Patten

Francis

Metz

Lopez-Bresnahan

Chang

Curtin

. The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler 2005; 11: 175–181.

29.

Patten

Beck

Williams

JVA

Barbui

Metz

. Major depression in multiple sclerosis. A population-based perspective. Neurology 2003; 61: 1524–1527.

30.

Patten

Svenson

Metz

. Descriptive epidemiology of affective disorders in multiple sclerosis. CNS Spectr 2005; 10: 365–371.

31.

Stewart

Lipton

Celentano

Reed

. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992; 267: 64–69.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.18 MB

0.00 MB